Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Appointment of Vice President of Business Strategy
March 08 2019 - 9:17AM
InvestorsHub NewsWire
Industry Veteran John P. Sentman to Lead Strategic Sales and
Partnering
MIRAMAR, FL -- March 8, 2019 -- InvestorsHub NewsWire --
Olaregen Therapeutix, a subsidiary of Generex Biotechnology
Corporation (www.generex.com) (OTCQB:GNBT)
(http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce
the appointment of John P. Sentman as Vice President of
Business Strategy. In his position, Mr. Sentman will lead and
coordinate the activities and operations of the business strategy
department responsible for executing all aspects of the
organization’s overall business strategy, sales and market
planning, and financial forecasts.
Mr. Sentman has over 30 years of experience in commercial,
marketing, and strategic planning roles within the medical device
industry, primarily in the wound care field. He joins Olaregen from
Integra Life Sciences where he was Senior Director of Global
Marketing for Regenerative Technologies, overseeing brand marketing
of the company’s soft tissue repair portfolio. Prior to
Integra, Mr. Sentman held various sales, management, and marketing
roles, both domestically and internationally over a 20-year career
with ConvaTec, a leading manufacturer of wound care products.
Mr. Sentman received his bachelor’s degree in finance from American
University’s School of Business.
“We are extremely pleased to have John leading business
strategy, market development and the commercial launch of
Excellagen,” said Anthony Dolisi, CEO of Olaregen and Chief
Commercial Officer of Generex. “His extensive wound care experience
and market knowledge will be instrumental to the company’s
commercial success.”
Mr. Sentman commented on his new position, “I welcome the
opportunity to launch and build the Excellagen brand as the leading
Cellular Tissue Product in treating hard-to-heal wounds, and I look
forward to working closely with the Olaregen team.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding
company with end-to-end solutions for patient centric care from
rapid diagnosis through delivery of personalized therapies. Generex
is building a new kind of healthcare company that extends beyond
traditional models providing support to physicians in an MSO
network, and ongoing relationships with patients to improve the
patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology
assets, medical devices, and diagnostics, the Company is focused on
an acquisition strategy of strategic businesses that complement
existing assets and provide immediate sources of revenue and
working capital. Recent acquisitions include a management services
organization, a network of pharmacies, clinical laboratory, and
medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex
Distribution Solutions (NDS), integrates our MSO network with a
pharmacy network, clinical diagnostic lab, durable medical
equipment company (DME-IQ) and dedicated call center.
About Olaregen Therapeutics
Olaregen Therapeutix, Inc. is a regenerative medicine company
focused on the development, manufacturing and commercialization of
products that fill unmet needs in the current wound care market.
The company aims to provide advanced healing solutions that
substantially improve medical outcomes while lowering the overall
cost of care. Olaregen's first product
introduction, Excellagen (flowable dermal
matrix) is a topically applied product for dermal wounds and other
indications. Excellagen is a FDA 510K cleared
device for a broad array of dermal wounds, including partial and
full thickness wounds, pressure ulcers, venous ulcers, diabetic
ulcers, chronic vascular ulcers, tunneled/undermined wounds,
surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser
surgery, podiatric, wound dehiscence), trauma wounds (abrasions,
lacerations, second-degree burns and skin tears) and draining
wounds, enabling Olaregen to
market Excellagen in multiple vertical markets.
Additionally, Excellagen can serve as an
Enabling Delivery Platform for pluripotent stem cells,
antimicrobial agents, small molecule drugs, DNA-Based Biologics,
conditioned cell media and peptides. Olaregen's initial focus will
be in advanced wound care including diabetic foot ulcers (DFU),
venous leg ulcers and pressure ulcers. Future products focusing on
innovative therapies in bone and joint regeneration comprise the
current pipeline. The company's mission is to become a significant
force in regenerative medicine and advance the science of
healing.
About our Service-Disabled Veteran-Owned Small Business
(SDVOSB)
This a Service-Disabled Veteran-Owned Small Business (SDVOSB)
that specializes in the sale, marketing, and distribution of
innovative medical products through a nationwide network of veteran
owned distribution services.
Cautionary Note Regarding Forward-Looking
Statements
This release and oral statements made from time to time by
Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan,"
"believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they
do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions
and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private
Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
Olaregen Contact:
Anthony J. Dolisi,
CEOanthony.dolisi@olaregen.com
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2023 to Apr 2024